Newsroom
2018
-
4,000 people attend Immunotec’s grand opening in Bogotá, Colombia
(October 17, 2018) -
Immunotec recognized in Direct Selling News April edition: A year of unprecedented growth and success
(April 16, 2018)
2017
-
Network marketing professional, Meredith Berkich, joins Immunotec as President of its U.S. business
(December 1, 2017) -
Immunotec announces completion of arrangement
(May 18, 2017) -
Immunotec announces receipt of final order for arrangement
(May 12, 2017) -
Immunotec shareholders approve arrangement with 1111267 B.C. LTD.
(May 11, 2017) -
Immunotec announces new director and reports on AGM results
(April 27, 2017) -
Immunotec files management proxy circular
(April 19, 2017) -
Q1-2017 - Period Ended January 31, 2017
(March 27, 2017) -
Immunotec enters into agreement to be acquired
(March 22, 2017) -
Immunotec provides an update on taxation matters in Mexico
(March 21, 2017) -
Immunotec reports record-breaking Convention attendance for its "brand evolution" launch
(February 16, 2017) -
Q4-2016 - Year Ended October 31, 2016
(January 26, 2017)
2016
-
Q3-2016 - Period Ended July 31, 2016
(September 16, 2016) -
Q2-2016 - Period Ended April 30, 2016
(June 16, 2016) -
Artemis Racing to work with Immunotec
(May 19, 2016) -
Immunotec announces the nomination of Mario Paradis to its Board of Directors and reports AGM results
(April 28, 2016) -
Immunotec renews material contract with Glanbia Nutritionals
(April 8, 2016) -
Q1-2016 - Period Ended January 31, 2016
(March 30, 2016) -
Immunotec announces executive promotions
(February 29, 2016) -
Immunocal® and Immunocal Platinum® certified by international testing company LGC
(February 25, 2016) -
Immunotec hosted record attendance at their 20th anniversary conventions
(February 24, 2016) -
Immunotec expands product offering with new skin care collection
(February 24, 2016) -
Q4-2015 - Year Ended October 31, 2015
(January 28, 2016)
2015
-
Immunotec Reports Issuance of Options
(September 22, 2015) -
Q3-2015 - Period Ended July 31, 2015
(September 17, 2015) -
Immunotec Resolves Taxation Matters in Mexico
(July 21, 2015) -
Immunotec Obtains $2,780,000 of New Financing
(July 20, 2015) -
Immunotec Reports Issuance of Options
(June 17, 2015) -
Q2-2015 - Period Ended April 30, 2015
(June 12, 2015) -
Immunocal® First to be Granted Strength and Performance Claim for a Stand-Alone Whey Protein by Health Canada
(May 12, 2015) -
Immunotec Ranks No. 97 in Sixth Annual DSN Global 100
(April 20, 2015) -
Q1-2015 - Period Ended January 31, 2015
(March 17, 2015) -
Q4-2014 - Year Ended October 31, 2014
(January 26, 2015)
2014
-
New Study Demonstrates Immunocal® Supplementation Increases Muscle Strength in Elderly Adults
(November 27, 2014) -
Immunotec Celebrates a Fourth Anniversary in Mexico and Announces the Appointment of a New Director
(October 30, 2014) -
Immunotec Opens New Sales Office in Commerce, California, U.S.A.
(October 21, 2014) -
Immunocal® used in novel Prehabilitation Study
(October 14, 2014) -
Q3-2014 - Period Ended July 31, 2014
(September 29, 2014) -
Immunotec launches The Immunotec Children's Fund at their 2014 Annual BBQ Event
(September 19, 2014) -
Immunotec to Appeal Recent Court Decision in Mexico
(September 15, 2014) -
Immunotec Files a Preliminary Short form Prospectus
(July 3, 2014) -
Rowing Canada Aviron and Immunotec Inc. Announce Winning Clubs for Visit from National Team Members
(June 11, 2014) -
Q2-2014 - Period Ended April 30, 2014
(May 29, 2014) -
Q1-2014 - Period Ended January 31, 2014
(March 27, 2014) -
Immunotec Announces Change in Marketing Management
(March 6, 2014) -
Immunotec Announces Completion of its International Convention in Mexico City
(February 25, 2014) -
Q4-2013 - Year Ended October 31, 2013
(February 13, 2014)
2013
-
Immunotec named an official sponsor of Rowing Canada Aviron
(December 3, 2013) -
Immunotec Announces Agreement
(November 4, 2013) -
Q3-2013 - Period Ended July 31, 2013
(September 12, 2013) -
Immunotec Announces a Corporate Update
(June 14, 2013) -
Q2-2013 - Period Ended April 30, 2013
(June 14, 2013) -
Immunotec Announces Recent Claim
(May 29, 2013) -
Immunotec Announces New CEO
(May 17, 2013) -
Immunotec Announces CEO Departure
(May 13, 2013) -
Immunotec Announces Normal Course Issuer Bid
(May 2, 2013) -
Q1-2013 - Period Ended January 31, 2013
(March 21, 2013) -
Immunotec Announces Grant of Options
(February 12, 2013) -
Q4-2012 - Year Ended October 31, 2012
(February 7, 2013)
2012
-
Q3-2012 - Period Ended July 31, 2012
(September 17, 2012) -
Q2-2012 - Period Ended April 30, 2012
(June 15, 2012) -
Proposed Share Consolidation
(February 20, 2012) -
Q4-2011 - Year Ended October 31, 2011
(February 20, 2012)
2011
-
Immunotec mourns the death of Dr. Gustavo Bounous
(December 29, 2011) -
Immunotec Announces closing $3.45M of New Financing
(September 15, 2011) -
Q3-2011 - Period Ended July 31, 2011 and Changes to Board of Directors
(September 9, 2011) -
Immunotec Appoints Mr. Daniel Audet as Vice-President of Marketing
(August 3, 2011) -
Immunotec and Nova Southeastern University (NSU) Collaborate on New Autism Study using Immunocal®
(July 13, 2011) -
Q2-2011 - Period Ended April 30, 2011
(June 17, 2011) -
Important New Research using Immunocal® Shows Promise in Lou Gehrig’s Disease
(June 13, 2011) -
Immunotec Signs Material Contract with Glanbia Nutritionals
(May 24, 2011) -
NSU and Immunotec Start Clinical Trail in Autism
(March 30, 2011) -
Q1-2011 - Period Ended January 31, 2011
(March 25, 2011) -
Q4-2010 - Year Ended October 31, 2010
(February 21, 2011) -
Immunotec Welcomes New President
(January 24, 2011)
2010
-
Immunotec mourns passing of Senior VP - Dr. Wulf Dröge, Ph.D.
(December 22, 2010) -
Immunotec CEO to retire at the end of the year
(December 9, 2010) -
Immunotec announces Stock Option Grant
(November 12, 2010) -
Q3-2010 - Period Ended July 31, 2010
(September 17, 2010) -
Immunotec announces changes to Management
(September 7, 2010) -
Immunotec appoints new Executive Chairman of the Board
(August 24, 2010) -
Immunotec mourns passing of Chairman Alex Konigsberg
(August 10, 2010) -
Q2-2010 - Period Ended April 30, 2010
(June 21, 2010) -
Immunotec to Present at the World Cancer Congress Conference In Singapore
(June 16, 2010) -
Immunotec Announces Closing of Previously Announced Transaction
(May 13, 2010) -
Immunotec Acquires Assets from Licensee in Mexico and Expands its Seamless Network
(May 3, 2010) -
Immunotec Appoints Robert M. Henry as New Director
(May 3, 2010) -
Q1-2010 - Period Ended January 31, 2010
(March 26, 2010) -
Q4-2009 - Year Ended October 31, 2009
(February 17, 2010)
2009
-
Immunotec Announces commencement of IMN 1207 US Lung Cancer Study funded by Moffitt Cancer Center CCOP Research Base
(December 7, 2009) -
Immunotec appoints Patrick Montpetit as Chief Financial Officer
(October 1, 2009) -
Q3-2009 - Period Ended July 31, 2009
(September 29, 2009) -
Immunotec Announces an Independent, Clinical Research Initiative at Beaumont Hospital’s Community Clinical Oncology Program (CCOP)
(August 3, 2009) -
Immunotec Inc. announces the closing of its Korean operations
(July 31, 2009) -
IMMUNOTEC announces important clinical research initiative: New study to be launched with the goal of improving the quality of the aging process.
(July 6, 2009) -
Q2-2009 - Period Ended April 30, 2009
(June 23, 2009) -
Election of New Director
(March 30, 2009) -
Q1-2009 - Period Ended January 31, 2009
(March 25, 2009) -
Q4-2008 - Year Ended October 31, 2008
(February 12, 2009)
2008
-
Immunotec congratulates 2008 Nobel Prize Winner in Medicine, Dr. Luc Montagnier
(October 23, 2008) -
Q3-2008 - Period Ended July 31, 2008
(September 24, 2008) -
Oral Tolerability of Cysteine-Rich Protein Isolate (Immunocal®) in Autism – A Pilot Study
(August 28, 2008) -
Immunotec Inc. Announces New Chief Operating Officer
(July 3, 2008) -
Q2-2008 - Period Ended April 30, 2008
(June 19, 2008) -
Testing Shows Athletes Can Safely Benefit from Immunocal®
(April 18, 2008) -
Q1-2008 - Period Ended January 31, 2008
(March 28, 2008) -
Q4-2007 - Year Ended October 31, 2007
(February 19, 2008) -
Cysteine-Rich Protein Prevents Weight Loss in Lung Cancer Patients: A Promising Intervention Study
(January 17, 2008)
2007
-
Health Canada approves health claim for Immunocal®
(November 13, 2007) -
Immunotec Inc. announces appointment of President and CEO James A. Northrop
(October 11, 2007) -
Q3-2007 - Period Ended July 31, 2007
(September 27, 2007) -
Immunotec Inc. announces retirement of President and CEO C.H. (Chuck) Roberts
(September 26, 2007) -
Q2-2007 - Period Ended April 30, 2007
(June 28, 2007) -
Q1-2007 - Period Ended January 31, 2007
(April 3, 2007) -
Immunotec Inc. to Commence Trading on the TSX Venture Exchange
(January 23, 2007)